Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Tampa, FloridaAges 18 years+ - NCT06310382RecruitingPhase 1/Phase 2
Study of GH55 for cancers with MAPK mutations
This trial tests a new drug, GH55, for people with advanced solid tumors that have a specific change in a group of genes called MAPK. It is for those who have tried other treatments or cannot have standard therapy. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06576635Recruiting
Chemotherapy study for advanced lung cancer
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Chicago, IllinoisAges 18 years+ - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT07070440RecruitingPhase 1/Phase 2
New combination therapy for advanced EGFR-mutated lung cancer
This trial tests a new combination therapy (DZD6008 plus other drugs) for people with advanced lung cancer that has an EGFR mutation and has stopped responding to a third-generation targeted therapy. It aims to find a better treatment option for these patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT06591650RecruitingPhase 2
Combination therapy for advanced gallbladder cancer
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04415853RecruitingPhase 3
Larotinib for advanced esophageal cancer with high EGFR
This phase 3 trial tests larotinib, a targeted cancer medicine, for people with advanced or recurrent esophageal cancer that has high EGFR. It aims to see if it works better than standard treatment approaches after the cancer has progressed twice.
Beijing, Beijing MunicipalityAges 18–80 - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT05438459RecruitingPhase 1/Phase 2
Pembrolizumab-based treatment given through an abdominal port
This early-phase study tests an antibody-based treatment given directly into the abdomen (through a port) for advanced stomach or pancreatic cancer that has spread in the lining of the belly or is causing abdominal fluid buildup. It’s designed for patients whose cancer has not responded to earlier chemotherapy, with the goal of improving cancer control and shrinking belly fluid.
Fukuoka, FukuokaAges 20 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+ - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT06069570RecruitingPhase 1
Gamma delta T cells and low dose radiation for advanced lung or bone cancer
This trial tests a new type of immune cell called gamma delta T cells combined with low-dose radiation to treat people with advanced lung cancer or solid tumors that have spread to the bone. It is only for patients who have already tried standard treatments and either didn't get better or couldn't tolerate them.
Tucson, ArizonaAges 18 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,319 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.